KBI Biopharma is an award winning CDMO providing fully-integrated, accelerated drug development & biomanufacturing services to pharmaceutical & biotechnology companies globally
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva,...
KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), No...
Oragenics Engages KBI Biopharma to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
KBI to Produce Material for Use in Upcoming Phase 2 Clinical Trial of Oragenics’ Intranasal Vaccine Candidate